Amyloid PET Scan Explained: Alzheimer's Patient Guide

If you or a loved one has been referred for an amyloid PET scan, or if your doctor has mentioned "ARIA monitoring" while discussing Alzheimer's treatment, this guide is for you. Two new drugs — lecanemab (Leqembi) and donanemab (Kisunla) — are changing Alzheimer's care, and understanding the brain imaging that goes with them puts you in a much stronger position to ask the right questions.

Key Takeaways

• An amyloid PET scan detects beta-amyloid plaques in the brain — a hallmark of Alzheimer's disease — and is required to confirm eligibility for the newest Alzheimer's treatments.
• ARIA (Amyloid-Related Imaging Abnormalities) is a potential side effect of anti-amyloid drugs, detected by brain MRI monitoring during treatment.
• Approximately 20–35% of patients on lecanemab develop ARIA; the majority of cases are asymptomatic and resolve on their own.
• People with the APOE4 gene variant have a higher risk of ARIA and require closer monitoring.
• The American College of Radiology and the American Society of Neuroradiology finalized a new Practice Parameter for ARIA imaging in 2026.

What Is an Amyloid PET Scan?

An amyloid PET scan is a specialized brain imaging test that uses a mildly radioactive tracer to detect beta-amyloid plaques in the brain. Beta-amyloid is a protein fragment that accumulates abnormally in Alzheimer's disease, forming sticky clumps between nerve cells. These plaques are one of the defining biological changes in Alzheimer's — and they begin building up 10 to 20 years before symptoms appear.

The scan works like this: a radiotracer is injected into your vein. The tracer travels to the brain and attaches to amyloid plaques. A PET scanner then detects radiation from the tracer, creating a detailed map of plaque distribution across the brain.

The FDA has approved three amyloid PET tracers:

• Amyvid (florbetapir F-18) — approved April 2012
• Vizamyl (flutemetamol F-18) — approved October 2013
• Neuraceq (florbetaben F-18) — approved March 2014

All three are considered clinically equivalent for confirming the presence of amyloid plaques.

Amyloid PET vs. a Standard Brain MRI

A standard brain MRI shows the structure of the brain — it can detect tumors, strokes, or shrinkage (atrophy) but cannot directly see amyloid plaques. An amyloid PET scan shows brain chemistry — specifically, where amyloid has accumulated. The two tests provide complementary information and are both used in Alzheimer's care.

Why You Might Need an Amyloid PET Scan

1. Confirming an Alzheimer's diagnosis. When memory symptoms are unclear or when the cause of dementia is uncertain, an amyloid PET scan gives doctors definitive biological evidence. A positive scan (amyloid present) supports an Alzheimer's diagnosis. A negative scan (no amyloid) steers the evaluation toward other causes of cognitive decline.

2. Qualifying for anti-amyloid therapy. The FDA-approved drugs lecanemab (Leqembi, approved January 2023) and donanemab (Kisunla, approved July 2024) work by clearing amyloid plaques from the brain. Both drugs require confirmation of amyloid positivity before starting treatment — and an amyloid PET scan is the gold standard for this confirmation. According to the Alzheimer's Association, these drugs slow cognitive decline by approximately 27–35% in patients with early Alzheimer's disease.

3. Monitoring treatment response. Repeat amyloid PET scans can show whether a drug is successfully reducing plaque burden over time.

What to Expect During the Scan

The entire visit typically takes 90–120 minutes:

1. Tracer injection (5 minutes): An IV is placed in your arm. The amyloid-targeting tracer is injected. You will feel nothing unusual.
2. Uptake period (30–90 minutes, depending on tracer): You rest quietly while the tracer binds to amyloid in your brain. You do not need to stay perfectly still during this phase.
3. PET scan (15–20 minutes): You lie on a table that moves slowly through the PET scanner. Your head rests in a comfortable support. The room is quiet.
4. You're done. No recovery time is needed. You can drive and resume normal activities.

No sedation is required. The total radiation dose is approximately 4–7 mSv — similar to a standard CT scan of the abdomen.

Understanding ARIA: What It Is and Why It Matters

ARIA stands for Amyloid-Related Imaging Abnormalities. It is a potential side effect seen on brain MRI in patients receiving anti-amyloid therapies like lecanemab and donanemab.

There are two types:

• ARIA-E (edema/effusion): Swelling of brain tissue or fluid buildup around the brain, visible on MRI as bright areas on FLAIR sequences. This is the more common type during early treatment.
• ARIA-H (hemosiderin deposits): Tiny spots of old blood (microhemorrhages) or superficial siderosis, visible as dark spots on certain MRI sequences.

How Common Is ARIA?

In clinical trials, ARIA occurred in approximately 21% of lecanemab-treated patients (all severity levels). About 3% experienced symptoms. For donanemab, ARIA rates were similar. Most cases are asymptomatic — found on routine MRI monitoring before the patient notices anything.

When symptoms do occur, they may include headache, dizziness, confusion, visual changes, or — rarely — seizures. Symptomatic ARIA is typically managed by pausing or adjusting the drug dose until the MRI abnormalities resolve, which usually happens within 12–16 weeks.

Who Is at Higher Risk for ARIA?

Patients who carry the APOE4 gene variant are at significantly higher risk. According to data from the CLARITY AD trial (lecanemab):

• Non-carriers: ~17% ARIA rate
• Single APOE4 copy (heterozygous): ~33% ARIA rate
• Two copies of APOE4 (homozygous): ~53% ARIA rate

Your neurologist may offer genetic testing for APOE4 before starting anti-amyloid treatment to clarify your individual risk.

Brain MRI Monitoring During Anti-Amyloid Treatment

Because ARIA can develop without obvious symptoms, regular brain MRI monitoring is a required part of anti-amyloid therapy protocols. A typical schedule looks like this:

• Baseline MRI before starting treatment
• MRI at Week 13 (after the 5th dose of lecanemab, or at the equivalent milestone for donanemab)
• MRI at Week 26 (after the 7th dose)
• Additional MRI if any symptoms develop between scheduled scans

Your MRI report during treatment will specifically describe whether any new ARIA-E or ARIA-H findings are present compared to previous scans. Radiologists use the same T2-FLAIR and susceptibility-weighted imaging sequences they use for standard brain MRIs. For an explanation of common brain MRI terminology, see our guide to reading a brain MRI report.

For a broader understanding of how PET scans work and how their reports are structured, see our PET scan report guide.

Frequently Asked Questions

What does a positive amyloid PET scan mean?

A positive result means beta-amyloid plaques are present in your brain at a level consistent with Alzheimer's disease. It does not necessarily mean you have symptoms today — amyloid builds up years before cognitive changes appear. Your neurologist will interpret the result alongside your clinical history, cognitive testing, and other biomarkers.

Can I have an amyloid PET scan if I already have a dementia diagnosis?

Yes. An amyloid PET scan is useful even after symptoms appear, especially to confirm whether Alzheimer's (rather than another cause) is responsible, or to determine whether you are eligible for anti-amyloid therapy. Current FDA-approved treatments are intended for early Alzheimer's — mild cognitive impairment or mild dementia stage.

Does Medicare cover the amyloid PET scan?

As of 2024, Medicare covers amyloid PET scans for patients with mild cognitive impairment or early Alzheimer's who are enrolled in a qualifying clinical care pathway as part of the Coverage with Evidence Development (CED) policy. Coverage rules continue to evolve; ask your neurologist's office and your insurance plan about current authorization requirements.

Is ARIA dangerous?

Most ARIA is mild and resolves without permanent harm. Serious ARIA events (causing significant neurological symptoms) occurred in less than 1% of participants in pivotal clinical trials. Your care team monitors for ARIA precisely so it can be caught early, before any significant harm occurs.

How long does it take to get amyloid PET results?

Amyloid PET results are typically reported within 24–48 hours. Your result will be classified as amyloid positive (plaques detected) or amyloid negative (no significant plaques). The report will also describe the distribution pattern of amyloid across brain regions.

---

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment decisions.